New insider activity at RenovoRx ( (RNXT) ) has taken place on April 18, 2025.
CMO Ramtin Agah has made a significant investment by purchasing 15,000 shares of RenovoRx stock, with the transaction valued at $13,500.
Recent Updates on RNXT stock
RenovoRx has recently experienced notable developments, including an increase in production of its FDA-cleared RenovoCath catheter-based device due to heightened demand from oncologists and interventional radiologists. The company announced a delay in filing its Form 10-K for the period ending December 31, 2024, citing the need to complete technical accounting requirements. Despite this delay, RenovoRx anticipates initial revenue from RenovoCath commercialization and a slight decrease in net loss. H.C. Wainwright initiated coverage with a Buy rating, highlighting the company’s novel catheter system for pancreatic cancer treatment and its potential market value. The analyst noted that RenovoRx’s shares are undervalued, presenting an attractive opportunity for long-term investors.
Spark’s Take on RNXT Stock
According to Spark, TipRanks’ AI Analyst, RNXT is a Underperform.
RenovoRx’s overall stock score reflects significant financial challenges, with persistent operational losses and negative cash flows. Technical analysis suggests ongoing bearish trends, while valuation is hampered by a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events further underscores the company’s uncertain outlook.
To see Spark’s full report on RNXT stock, click here.
More about RenovoRx
YTD Price Performance: -24.26%
Average Trading Volume: 140,013
Technical Sentiment Signal: Buy
Current Market Cap: $32.89M